Indolent Lymphoma

16 registered clinical trials studyying Indolent Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphom NCT07441954	Institute of Hematology & Blood Diseases Hospital, China	Phase 1 / Phase 2
Not Yet Recruiting	Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma NCT07459608	Henan Cancer Hospital	Phase 2
Recruiting	A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macrog NCT06986174	Shayna Sarosiek, MD	Phase 2
Unknown	Low-dose Radiotherapy in iNHL NCT05543070	Chinese Academy of Medical Sciences	Phase 2
Unknown	PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	Phase 1
Active Not Recruiting	NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678	Nkarta, Inc.	Phase 1
Unknown	Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period NCT04957693	Tel-Aviv Sourasky Medical Center	N/A
Terminated	Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035	TG Therapeutics, Inc.	Phase 1
Terminated	Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunothe NCT04431635	University of Michigan Rogel Cancer Center	Phase 1
Completed	Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT03424603	Sutro Biopharma, Inc.	Phase 1
Completed	1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221	University of Maryland, Baltimore	Phase 2
Unknown	Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma NCT03261349	National Taiwan University Hospital	Phase 2
Completed	A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies NCT01263899	S*BIO	Phase 2
Completed	Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymp NCT00980395	University of Arizona	Phase 2
Unknown	11C-Acetate PET/CT Non-FDG-Avid Tumors NCT00687778	Tel-Aviv Sourasky Medical Center	—
Terminated	Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma NCT00954005	German Low Grade Lymphoma Study Group	Phase 1 / Phase 2